Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,138,824
  • Shares Outstanding, K 142,609
  • Annual Sales, $ 330,530 K
  • Annual Income, $ -145,220 K
  • 60-Month Beta 1.39
  • Price/Sales 10.02
  • Price/Cash Flow N/A
  • Price/Book 2.27
Trade DNLI with:

Options Overview Details

View History
  • Implied Volatility 72.46% ( +11.23%)
  • Historical Volatility 54.04%
  • IV Percentile 81%
  • IV Rank 56.42%
  • IV High 96.66% on 05/01/24
  • IV Low 41.13% on 09/27/23
  • Put/Call Vol Ratio 2.00
  • Today's Volume 3
  • Volume Avg (30-Day) 206
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 2,987
  • Open Int (30-Day) 3,907

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.69
  • Number of Estimates 12
  • High Estimate -0.53
  • Low Estimate -0.80
  • Prior Year 1.30
  • Growth Rate Est. (year over year) -153.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.81 +15.58%
on 06/03/24
23.87 -8.92%
on 06/24/24
+3.18 (+17.13%)
since 05/31/24
3-Month
14.56 +49.31%
on 04/25/24
23.87 -8.92%
on 06/24/24
+2.36 (+12.18%)
since 04/02/24
52-Week
14.56 +49.31%
on 04/25/24
30.79 -29.39%
on 07/19/23
-7.77 (-26.33%)
since 06/30/23

Most Recent Stories

More News
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines

/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...

DNLI : 21.74 (-1.23%)
FHTX : 5.44 (-6.85%)
MRNA : 117.07 (+0.97%)
OMGA : 2.07 (-8.00%)
SANA : 5.35 (-2.19%)
MCRB : 0.7010 (-2.91%)
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFoundâ„¢ Therapeutics, a company pioneering the discovery of a vastly expanded...

DNLI : 21.74 (-1.23%)
FHTX : 5.44 (-6.85%)
MRNA : 117.07 (+0.97%)
OMGA : 2.07 (-8.00%)
SANA : 5.35 (-2.19%)
MCRB : 0.7010 (-2.91%)
Flagship Pioneering Named to Fortune's 2023 "Change the World" List

/PRNewswire/ -- Flagship Pioneering today announced it has been named to FORTUNE's 2023 "Change the World" list, an annual global ranking of companies that...

DNLI : 21.74 (-1.23%)
FHTX : 5.44 (-6.85%)
MRNA : 117.07 (+0.97%)
OMGA : 2.07 (-8.00%)
SANA : 5.35 (-2.19%)
MCRB : 0.7010 (-2.91%)
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business...

DNLI : 21.74 (-1.23%)
FHTX : 5.44 (-6.85%)
MRNA : 117.07 (+0.97%)
OMGA : 2.07 (-8.00%)
SANA : 5.35 (-2.19%)
MCRB : 0.7010 (-2.91%)
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as...

DNLI : 21.74 (-1.23%)
FHTX : 5.44 (-6.85%)
MRNA : 117.07 (+0.97%)
OMGA : 2.07 (-8.00%)
SANA : 5.35 (-2.19%)
MCRB : 0.7010 (-2.91%)
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Ampersand Biomedicines, a company programming smarter medicines that act...

DNLI : 21.74 (-1.23%)
FHTX : 5.44 (-6.85%)
MRNA : 117.07 (+0.97%)
OMGA : 2.07 (-8.00%)
SANA : 5.35 (-2.19%)
MCRB : 0.7010 (-2.91%)
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

DNLI : 21.74 (-1.23%)
RARE : 40.96 (-0.39%)
SRPT : 154.20 (-1.63%)
PFE : 27.83 (-1.38%)
EXEL : 22.15 (-0.45%)
MRNA : 117.07 (+0.97%)
UTHR : 317.05 (-0.61%)
BIIB : 228.82 (-1.27%)
SNY : 48.54 (-2.12%)
LLY : 906.71 (-0.84%)
Why Shares of Denali Therapeutics Are Up Monday

Analysts maintained their buy ratings on the clinical-stage biotech company.

DNLI : 21.74 (-1.23%)
Cellarity Strengthens Executive Leadership Team

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointments of John Leaman, M.D., M.B.A., as Chief Financial Officer...

IMPL : 0.0400 (-27.27%)
SELB : 0.8812 (-8.00%)
MDGN : 5.57 (+3.15%)
DNLI : 21.74 (-1.23%)
EVLO : 0.0001 (unch)
FHTX : 5.44 (-6.85%)
MRNA : 117.07 (+0.97%)
OMGA : 2.07 (-8.00%)
SANA : 5.35 (-2.19%)
MCRB : 0.7010 (-2.91%)
Flagship Pioneering Unveils Ampersand Biomedicines to Create Highly Effective Medicines That Are Programed to Act Only Where Needed

Flagship Pioneering, the bioplatform innovation company, today unveiled Ampersand Biomedicines, a company creating programmable medicines that are safer, more tolerable, and effective by acting at the...

DNLI : 21.74 (-1.23%)
EVLO : 0.0001 (unch)
FHTX : 5.44 (-6.85%)
MRNA : 117.07 (+0.97%)
OMGA : 2.07 (-8.00%)
SANA : 5.35 (-2.19%)
MCRB : 0.7010 (-2.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program...

See More

Key Turning Points

3rd Resistance Point 23.00
2nd Resistance Point 22.59
1st Resistance Point 22.17
Last Price 21.74
1st Support Level 21.34
2nd Support Level 20.93
3rd Support Level 20.51

See More

52-Week High 30.79
Fibonacci 61.8% 24.59
Fibonacci 50% 22.68
Last Price 21.74
Fibonacci 38.2% 20.76
52-Week Low 14.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar